Wichtige Arbovirosen bei Tropenrückkehrern: Dengue, Chikungunya, Zika

Arbovirus-Infektionen sind wichtige Differenzialdiagnosen bei Tropenrückkehrern mit Fieber, Gliederschmerzen und Exanthem. Arboviren haben sich in den letzten Jahrzehnten stark verbreitet – ausschlaggebend sind Bevölkerungswachstum, Urbanisierung, Globalisierung, Flugreisen und Klimawandel. In diesem Beitrag stellen wir die in Europa reisemedizinisch wichtigsten Arbovirosen vor: Dengue-Fieber, Chikungunyavirus- und Zikavirus-Erkrankung.

Abstract

Arboviral infections are an important differential diagnosis in returning travelers with fever, muscle or joint pain and rash. Arboviruses have spread widely around the globe in the last decades. The most common arboviral infections in returning travelers from tropical and subtropical areas are dengue, chikungunya and zika. Their most important vectors, Aedes (Stegomyia) mosquito species, have adapted to the urban environment, which enabled arboviruses to establish urban transmission cycles. Population growth, urbanization, globalization, modern means of transportation and global warming are speeding up their spread.

Laboratory confirmation of an arboviral infection can generally be obtained by direct virus detection (PCR, antigen test) in the first week of illness; from the second week of illness serology can be used. Treatment is mostly symptomatic.

Dengue fever is the most common cause of fever in returning travelers from South-East Asia. Patients have to be educated about and observed for warning signs of severe dengue that can rarely develop around day 5 of the disease and is marked by a rise in hematocrit.

Chikungunya mostly occurs in epidemics and is characterized by severe and often long-lasting arthritis.

Preconceptional screening for zika virus infection is not recommended. Instead, travelers should delay conception for up to three months after returning from a zika endemic area.

Dengue, chikungunya and zika vaccine development has been hampered by difficulties, for example antibody-dependent-enhancement or the unpredictability of outbreaks, and up to now no vaccines for travelers have been licensed. Yet several promising vaccine candidates are currently under development.

Schlüsselwörter

Arbovirose - Dengue-Fieber - Chikungunyavirus-Erkrankung - Zikavirus-Erkrankung

Key words

arboviral disease - dengue - chikungunya - zika

Publication History

Article published online:
07 June 2022

• Literatur

• 1 Musso D, Gubler DJ. Zika Virus. Clin Microbiol Rev 2016; 29: 487-524 DOI: 10.1128/CMR.00072-15.
• 2 Valentine MJ, Murdock CC, Kelly PJ. Sylvatic cycles of arboviruses in non-human primates. Parasit Vectors 2019; 12: 463 DOI: 10.1186/s13071-019-3732-0.
• 3 Weaver SC, Charlier C, Vasilakis N. et al. Zika, Chikungunya, and Other Emerging Vector-Borne Viral Diseases. Annu Rev Med 2018; 69: 395-408 DOI: 10.1146/annurev-med-050715-105122.
• 4 Kraemer MUG, Reiner Jr RC, Brady OJ. et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol 2019; 4: 854-863 DOI: 10.1038/s41564-019-0376-y.
• 5 Wilder-Smith A, Ooi EE, Horstick O. et al. Dengue. Lancet 2019; 393: 350-363 DOI: 10.1016/S0140-6736(18)32560-1.
• 6 Falkenhorst GEJ, Frank C, Lachmann R. et al. Reiseassoziierte Krankheiten 2019. Epid Bull 2020; 2020: 7-20
• 7 Guzman MG, Harris E. Dengue. Lancet 2015; 385: 453-465 DOI: 10.1016/S0140-6736(14)60572-9.
• 8 World Health Organization (WHO). Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. Revised and expanded edition. WHO Regional Office for South-East Asia. 2011 Im Internet (Stand: 07.04.2022): https://apps.who.int/iris/handle/10665/204894
• 9 Sangkaew S, Ming D, Boonyasiri A. et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis 2021; 21: 1014-1026 DOI: 10.1016/S1473-3099(20)30601-0.
• 10 Wilder-Smith A. Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. J Travel Med 2018; 25 DOI: 10.1093/jtm/tay057.
• 11 Wilder-Smith A. Dengue vaccine development: status and future. Bundesgesundheitsbl 2020; 63: 40-44 DOI: 10.1007/s00103-019-03060-3.
• 12 Burt FJ, Chen W, Miner JJ. et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis 2017; 17: e107-e117 DOI: 10.1016/S1473-3099(16)30385-1.
• 13 Pathak H, Mohan MC, Ravindran V. Chikungunya arthritis. Clin Med (Lond) 2019; 19: 381-385 DOI: 10.7861/clinmed.2019-0035.
• 14 Baud D, Gubler DJ, Schaub B. et al. An update on Zika virus infection. Lancet 2017; 390: 2099-2109 DOI: 10.1016/S0140-6736(17)31450-2.
• 15 Kumar R, Ahmed S, Parray HA. et al. Chikungunya and arthritis: An overview. Travel Med Infect Dis 2021; 44: 102168 DOI: 10.1016/j.tmaid.2021.102168.
• 16 Reisinger EC, Tschismarov R, Beubler E. et al. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 2019; 392: 2718-2727 DOI: 10.1016/S0140-6736(18)32488-7.
• 17 Musso D, Ko AI, Baud D. Zika Virus Infection – After the Pandemic. N Engl J Med 2019; 381: 1444-1457 DOI: 10.1056/NEJMra1808246.
• 18 Chen LH, Hamer DH. Zika virus and sexual transmission: updated preconception guidance. J Travel Med 2018; 25 DOI: 10.1093/jtm/tay095.
• 19 Eppes C, Rac M, Dunn J. et al. Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic. Am J Obstet Gynecol 2017; 216: 209-225 DOI: 10.1016/j.ajog.2017.01.020.
• 20 Robert Koch-Institut (RKI). Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2020. Berlin: 2021 DOI: 10.25646/8773